Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920238 · ClinicalTrials.gov registry record · Phase 1
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
A Phase 1 study of Anxiety and Depression, Anxiety, sponsored by Trustees of Dartmouth College.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06920238: Recruiting Phase 1 study of Anxiety and Depression, Anxiety, sponsored by Trustees of Dartmouth College.
NCT06920238 is a Phase 1 study of Anxiety and Depression, Anxiety that is actively recruiting participants, run by Trustees of Dartmouth College. The registered enrollment target is 15 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920238, a Phase 1 study of Anxiety and Depression, Anxiety, is actively recruiting participants, sponsored by Trustees of Dartmouth College.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression? Participants will * Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview
Primary Outcome
Feasibility of the application is measured by engagement rates of participants. Engagement rates will be quantified based on the frequency and duration of interactions with the application during the clinical trial period.
Conditions Studied
Interventions
- DEVICE Therabot-CALM
Study Locations (1)
New Hampshire
- 46 Centerra Parkway, Suite 300, Office #333S - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-04-13 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT06920238 shows while recruiting
NCT06920238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Therabot-CALM is the first listed.
NCT06920238 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT06920238 about?
NCT06920238 is a clinical study titled "Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use". The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibi...
What is the current status of trial NCT06920238?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2025-04-13. Estimated completion is 2025-12.
What conditions does trial NCT06920238 study?
This clinical trial studies the following conditions: Anxiety, Depression, Anxiety, Cannabis Use Disorder, Depression - Major Depressive Disorder.
What interventions are being tested in trial NCT06920238?
The interventions under investigation include: Therabot-CALM (DEVICE).
Who is sponsoring clinical trial NCT06920238?
This trial is sponsored by Trustees of Dartmouth College, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920238 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06920238's enrollment target sits among peer trials
15 345th of 364 higher than 18 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-Label Psilocybin Study in Transdiagnostic Population
RECRUITING · Phase 1
-
The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety
RECRUITING · Phase 1
-
Autonomous Digital CBT Intervention for Opioid Use Disorder in Individuals With Co-Occurring Internalizing Disorders
ACTIVE NOT RECRUITING · Phase 1
-
Transforming Psychotherapy for Chronically Ill Patients
COMPLETED · Phase 1
-
Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes
COMPLETED · Phase 1
-
Bright Light: A Novel Treatment for Anxiety
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI